InvestorsHub Logo
Followers 24
Posts 819
Boards Moderated 0
Alias Born 04/15/2007

Re: None

Sunday, 04/05/2020 2:47:54 PM

Sunday, April 05, 2020 2:47:54 PM

Post# of 83386
In light of the new patent allowance the meeting with the FDA back in January takes on a new meaning. At the time I thought CVSI seemed the odd man out of this coalition. All the other companies are providers of Pharmaceutical grade cannabinoids. CVSI used the cbd from Noramco in the
recent study and affidavit submitted to the patent office that helped turn the patent approval around. Noramco is part of Purisys. Two of the other companies are making cannabinoids thru cellular agriculture. Just trying to figure out if there is a common denominator why cvsi is in this coalition.

Event Date: 01/16/2020
Location: Silver Spring, MD
Subject: Listening Session with the Cannabidiol (CBD) Coalition
FDA Participant/Group: ALISON THOMPSON; JOSEPH FRANKLIN; RACHEL OSTERMAN; CARA WELCH; LOWELL SCHILLER; SHARON MAYL; MICHAEL LEVY; MELISSA ROBB; CASSANDRA TAYLOR; DENNIS KEEFE; APRIL ALEXANDROW; STEVEN TAVE; REBECCA GOLDBERG; SHERENE SEPEHRI;
Non FDA Participant/Group: Brendan Carroll, Marc Scheineson (Alston & Bird LLP); Cynthia Bryant (Demetrix, Inc.); Bill Grubb (Noramco); Angelo Fefekos, Etan Bendheim, Jeremy Friedberg (LAVVAN, Inc.); Wendi Young (Mile High Labs); Josh Hoerner, Scott Warner (Purisys); Douglas “Duffy” McKay, Joseph Dowling (CV Sciences, Inc.); Trevor Peters (Willow Biosciences)